Stockscreener 앱 받기
0.178
8.65%
-0.0169
시간 외 거래:
.17
-0.008
-4.49%
전일 마감가:
$0.1949
열려 있는:
$0.19
하루 거래량:
333.89K
Relative Volume:
0.07
시가총액:
$4.11M
수익:
-
순이익/손실:
$-20.26M
주가수익비율:
-0.0208
EPS:
-8.54
순현금흐름:
$-8.25M
1주 성능:
-7.07%
1개월 성능:
-4.89%
6개월 성능:
-43.97%
1년 성능:
-83.36%
1일 변동 폭
$0.178
$0.19
1주일 범위
$0.178
$0.20
52주 변동 폭
$0.1617
$3.43
Oragenics Inc Stock (OGEN) Company Profile
명칭
Oragenics Inc
전화
813-286-7900
주소
4902 Eisenhower Boulevard, Suite 125, Tampa, FL
OGEN을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OGEN
Oragenics Inc
|
0.178 | 4.11M | 0 | -20.26M | -8.25M | -8.54 |
|
VRTX
Vertex Pharmaceuticals Inc
|
499.76 | 127.64B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
603.40 | 65.95B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ARGX
Argen X Se Adr
|
656.58 | 37.92B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
273.84 | 32.98B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
254.68 | 26.89B | 3.81B | -644.79M | -669.77M | -6.24 |
Oragenics Inc 주식(OGEN)의 최신 뉴스
Oragenics Appoints New CEO and Amends Employment Terms By Investing.com - Investing.com Nigeria
Oragenics Appoints New CEO and Amends Employment Terms - Investing.com Australia
Oragenics Appoints Janet Huffman as CEO and CFO - TipRanks
StockNews.com Initiates Coverage on Oragenics (NYSE:OGEN) - Defense World
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brai - GuruFocus
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference | OGEN Stock News - GuruFocus
Oragenics, Inc. to Present at the 15th Annual Traumatic Brain Injury Conference on Advances in mTBI Detection and Management - Nasdaq
Oragenics, Inc. to Participate at the 15th Annual Traumatic Brain Injury Conference - GlobeNewswire
Oragenics (NYSE:OGEN) Now Covered by Analysts at StockNews.com - Defense World
Oragenics, Inc. Announces Health and Disability Ethics Committee - GuruFocus
Oragenics, Inc. Announces Health and Disability Ethics Committee Submission for Phase IIa Concussion Trial - The Manila Times
Oragenics Announces Health And Disability Ethics Committee Submission - MarketScreener
Oragenics, Inc. Participates in the 3rd Nasal Formulation & Delivery Summit - GlobeNewswire
Oragenics gears up for Phase II trials, appoints new CEO - MSN
Oragenics (NYSE:OGEN) Coverage Initiated at StockNews.com - Defense World
OGEN stock touches 52-week low at $0.19 amid sharp annual decline By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.19 amid sharp annual decline - Investing.com
OGEN stock touches 52-week low at $0.24 amid sharp annual decline - Investing.com Australia
Oragenics (NYSE:OGEN) Now Covered by StockNews.com - Defense World
Oragenics reports progress in concussion drug development By Investing.com - Investing.com South Africa
OGEN stock touches 52-week low at $0.24 amid sharp annual decline By Investing.com - Investing.com South Africa
Oragenics reports progress in concussion drug development - Investing.com
Oragenics Provides Q1 2025 Shareholder Update On Strategic And Financial Progress - MarketScreener
Oragenics, Inc. Provides Q1 2025 Shareholder Update on Strategic and Financial Progress - The Manila Times
Oragenics (NYSE:OGEN) Coverage Initiated by Analysts at StockNews.com - Defense World
Investornewsbreaks Oragenics Inc. Files 2024 Annual Report, Addresses Going Concern Status - MENAFN.COM
CEMATRIX To Report Fourth Quarter and 2024 Year End Results on March 26, 2025 - The Manila Times
Oragenics, Inc. Announces Filing of 2024 Annual Report on Form 10-K - TradingView
Oragenics, Inc. Files Annual Report for 2024, Receives Unqualified Audit Opinion - Nasdaq
Going Concern Alert: Oragenics Brain Treatment Pipeline Faces Critical Financial Test - StockTitan
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles - Investing.com Australia
OGEN Stock Plummets to 52-Week Low of $0.25 Amid Market Struggles By Investing.com - Investing.com South Africa
Oragenics Inc. (OGEN) reports earnings - qz.com
StockNews.com Begins Coverage on Oragenics (NYSE:OGEN) - Defense World
The Oragenics Inc (OGEN) Stock Is Headed for a Correction - US Post News
Digital Risk Inc. Launches Digital Footprint Exposure Assessment Tool to Combat Human Cybersecurity Risks - The Manila Times
Oragenics, Inc. Submits Investigator's Brochure for Phase II Clinical Trial of ONP-002 in Australia for Mild Traumatic Brain Injury - Nasdaq
Oragenics, Inc. Submits Investigator’s Brochure for Phase - GlobeNewswire
Oragenics, Inc. Submits Investigator’s Brochure for Phase II Clinical Trial of ONP-002 in Mild Traumatic Brain Injury (mTBI) - Yahoo Finance UK
Oragenics, Inc. Chief Medical Officer, Dr. James P. Kelly, to Present at the Emergencies in Medicine Conference on Advancing Concussion Treatment - The Manila Times
Oragenics Inc (OGEN) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.52%
0.52%
자본화:
|
볼륨(24시간):